New validated spectrofluorimetric protocol for colistin assay through condensation with 2,2-dihydroxyindan-1,3-dione: application to content uniformity testing.
Tamer Z AttiaMahmoud A AbdelmajedMahmoud A OmarSultan S Al ThagfanKhalid M Badr El-DinPublished in: RSC advances (2022)
A new, cost-effective and sensitive spectroscopic assay for the quantification of Colistin Sulfate (CS) and its prodrug colistimethate sodium (CMS) has been developed and validated. The validated technique depends on the condensation of the studied drug with 2,2-dihydroxyindan-1,3-dione (ninhydrin) and phenylacetaldehyde using Teorell and Stenhagen buffer (pH = 6) to yield a fluorescent product that is estimated at emission wavelength ( λ em = 474 nm) after excitation wavelength ( λ ex = 390 nm). The reaction's affecting factors were carefully studied and adjusted accurately. Over the following range (0.4-2.4 μg mL -1 ), the produced calibration plot looked rectilinear, and the estimated limits of detection and quantification (LOD and LOQ) were 0.051 & 0.154 μg mL -1 respectively. The recommended approach was utilized to evaluate market products containing the investigated drug. Moreover, content uniformity testing was employed as a new procedure not found in the previously reported fluorimetric technique.
Keyphrases
- escherichia coli
- acinetobacter baumannii
- pseudomonas aeruginosa
- klebsiella pneumoniae
- multidrug resistant
- high throughput
- drug resistant
- gram negative
- photodynamic therapy
- label free
- solid state
- randomized controlled trial
- molecular docking
- adverse drug
- quantum dots
- health insurance
- light emitting
- minimally invasive
- mass spectrometry
- real time pcr
- cystic fibrosis
- drug induced
- loop mediated isothermal amplification
- atomic force microscopy
- high resolution
- single molecule
- electronic health record
- high speed
- electron transfer